GLPwatch
Cross-Sectional Analysis of Adverse Dermatologic Events Reported to the FDA After Use of GLP-1 Agonists.
J Drugs Dermatol · 2024
Last updated 2026-07-17| Journal | J Drugs Dermatol, 2024 |
|---|---|
| Citations | 8 |
| Relative citation ratio | 1.76 |
| NIH percentile | 70 |
| Molecules | — |
Full record and abstract on PubMed 39231072 ↗